文献速递前列腺癌

前列腺磁共振成像联合或不联合磁共振靶向活检与系统活检检测前列腺癌:Cochrane系统评价与Meta分析

Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis.
PubMed 文献 · Eur Urol · 2019-07-18

该系统评价与Meta分析比较了磁共振成像(MRI)路径(MRI联合或不联合MRI靶向活检)与系统活检对临床显著前列腺癌(ISUP分级≥2)的诊断准确性。结果显示,在30%基线患病率下,MRI路径的敏感度为0.72、特异度为0.96,系统活检的敏感度为0.63、特异度为1.00;MRI路径在活检初治男性中显著癌检出比(1.05)与系统活检相近,在既往活检阴性男性中检出比(1.44)更高,且非显著癌检出比较低。作者认为MRI路径在显著和非显著前列腺癌检出方面结果最有利,但证据确定性因研究局限性而降低,且MRI路径仍会漏诊部分显著癌。

要点

  • 在30%基线患病率下,MRI路径敏感度0.72、特异度0.96,系统活检敏感度0.63、特异度1.00。
  • 活检初治男性中MRI路径与系统活检的显著癌检出比为1.05(95%CI 0.95-1.16)。
  • 既往活检阴性男性中MRI路径与系统活检的显著癌检出比为1.44(95%CI 1.19-1.75)。

核心结论

  • 与系统活检相比,MRI路径在显著和非显著前列腺癌检出方面结果最有利。
  • 证据确定性因研究局限性而降低。
  • MRI路径仍会漏诊部分显著前列腺癌男性,因此该领域需进一步研究。

研究设计与样本

  • Cochrane系统评价与Meta分析,系统检索文献,纳入任何横断面研究,要求研究调查一种或多种经参考标准验证的指数试验,并配对检测MRI路径与系统活检。
  • 参考标准为模板引导活检,目标条件为临床显著前列腺癌(国际泌尿病理学会分级2级或更高),人群为活检初治男性或既往活检阴性男性(或两者混合)。
  • 采用QUADAS-2评估质量,采用GRADE评估证据确定性。

主要发现

  • 在30%基线患病率下,MRI路径(敏感度0.72,95%CI 0.60-0.82;特异度0.96,95%CI 0.94-0.98;8项研究)每1000名男性中可能产生216例(180-246)真阳性、28例(14-42)假阳性、672例(658-686)真阴性和84例(54-120)假阴性。
  • 在30%基线患病率下,系统活检(敏感度0.63,95%CI 0.19-0.93;特异度1.00,95%CI 0.91-1.00;4项研究)每1000名男性中可能产生189例(57-279)真阳性、0例(0-63)假阳性、700例(637-700)真阴性和111例(21-243)假阴性。
  • 直接比较MRI路径与系统活检对显著疾病的检出,活检初治男性中合并检出比为1.05(95%CI 0.95-1.16;20项研究),既往活检阴性男性中为1.44(95%CI 1.19-1.75;10项研究)。
  • 对非显著疾病,活检初治男性中合并检出比为0.63(95%CI 0.54-0.74),既往活检阴性男性中为0.62(95%CI 0.44-0.88)。

关键数值与推荐

  • 临床显著前列腺癌定义为国际泌尿病理学会分级2级或更高。
  • MRI路径在30%基线患病率下的敏感度为0.72(95%CI 0.60-0.82),特异度为0.96(95%CI 0.94-0.98)。
  • 系统活检在30%基线患病率下的敏感度为0.63(95%CI 0.19-0.93),特异度为1.00(95%CI 0.91-1.00)。
  • 活检初治男性中MRI路径与系统活检的显著癌检出比为1.05(95%CI 0.95-1.16)。
  • 既往活检阴性男性中MRI路径与系统活检的显著癌检出比为1.44(95%CI 1.19-1.75)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 证据确定性因研究局限性而降低。
  • MRI路径仍会漏诊部分显著前列腺癌男性。
  • 该领域需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Magnetic resonance imaging (MRI), with or without MRI-targeted biopsy (MRI pathway), is an alternative test to systematic transrectal ultrasonography-guided biopsy in men suspected of having prostate cancer. At present, evidence on which test to use is insufficient to inform detailed evidence-based decision making. OBJECTIVE: To determine the diagnostic accuracy of the index tests MRI only, MRI-targeted biopsy, MRI pathway, and systematic biopsy, as compared with template-guided biopsy (reference standard), in detecting clinically significant prostate cancer, defined as International Society of Urological Pathology grade 2 or higher, in biopsy-naive men or those with a prior-negative biopsy (or mix of both). EVIDENCE ACQUISITION: We systematically searched the literature and considered for inclusion any cross-sectional study if it investigated (1) one or more index tests verified by the reference standard, and (2) paired testing of the MRI pathway with systematic biopsy. Quality and certainty of evidence were assessed by the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) and Grading of Recommendations Assessment, Development and Evaluation, respectively. EVIDENCE SYNTHESIS: Accuracy analyses: Using a baseline cancer prevalence of 30%, MRI pathway (sensitivity 0.72 [95% confidence interval {CI}: 0.60-0.82]; specificity 0.96 [0.94-0.98]; eight studies) may result in 216 (180-246) true positives, 28 (14-42) false positives, 672 (658-686) true negatives, and 84 (54-120) false negatives per 1000 men. Systematic biopsy (sensitivity 0.63 [0.19-0.93]; specificity 1.00 [0.91-1.00]; four studies) may result in 189 (57-279) true positives, 0 (0-63) false positives, 700 (637-700) true negatives, and 111 (21-243) false negatives per 1000 men. Agreement analyses: With a direct comparison of the MRI pathway with systematic biopsy concerning significant disease, we found pooled detection ratios of 1.05 (95% CI: 0.95-1.16; 20 studies) in biopsy-naive men and 1.44 (1.19-1.75; 10 studies) in men with a prior-negative biopsy. Concerning insignificant disease, we found detection ratios of 0.63 (95% CI: 0.54-0.74), and 0.62 (95% CI: 0.44-0.88), respectively. CONCLUSIONS: MRI pathway had the most favourable outcome in significant and insignificant prostate cancer detection compared with systematic biopsy. The certainty in our findings was reduced by study limitations. PATIENT SUMMARY: We reviewed recent advances in prostate biopsy by magnetic resonance imaging (MRI) guidance and targeting for prostate cancer detection in comparison with standard diagnosis by systematic biopsies. The findings of this Cochrane review suggest that MRI pathway is better than systematic biopsies in making a correct diagnosis of clinically important prostate cancer and reducing redundant biopsies and the detection of unimportant cancers substantially. However, MRI pathway still misses some men with important prostate cancer. Therefore, further research in this area is important.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Drost FH, Osses D, Nieboer D, et al. Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis. Eur Urol. 2019. PMID: 31326219. doi:10.1016/j.eururo.2019.06.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。